News | August 18, 2022
ProBioGen enters into master service agreement with NextPoint Therapeutics
The integrated services ensure that NextPoint can bring their molecule to the clinic in a timely manner.
The integrated services ensure that NextPoint can bring their molecule to the clinic in a timely manner.
Collaboration supports multiple discovery efforts, including vaccines
The WAVEsystem with the WAVEcontrol 4.0 embedded
This next-generation bivalent COVID-19 vaccine candidate, BNT162b5, consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain (wild-type) and an Omicron variant.
The Elecsys Amyloid Plasma Panel has the potential to ensure better identification of patients that require further confirmatory testing, supporting a more timely and accessible diagnosis.
ExoBrite antibody conjugates are validated and optimized for bright and specific detection of exosome markers
The FDA's Orphan Drug Designation is granted to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
Up to $30m funding will be provided to advance an innovative vaccine technology that could protect against current and future SARS-CoV-2 variants and other SARS-like Betacoronaviruses.
Fermentation-based manufacturing leverages Evonik’s biotechnology platform
Subscribe To Our Newsletter & Stay Updated
